Research
Hormonal
NAFLD, particularly biopsy-proven NASH, is associated with a greater prevalence of Chronic Kidney Disease (CKD) and an increased risk of incident CKD.
If you have fatty liver, you are at higher risk for kidney disease, even if you do not have diabetes or high blood pressure. Regular kidney function tests (eGFR and urine analysis) are recommended as part of your standard care to detect early signs of kidney stress.
ModerateSupportsMEDIUM confidence
NAFLD (in particular, biopsy-proven NASH) is associated with a greater prevalence of CKD (20% to 50% of patients). USS-defined NAFLD carries a 1.5-2-fold adjusted risk of incident CKD.
Why this rating
Supported by multiple prospective studies, but conflicting data exists in large population-based databases (NHANES) regarding ultrasound-defined NAFLD.
Source
Extrahepatic complications of nonalcoholic fatty liver disease
Matthew J. Armstrong et al. · Hepatology · 2013
DOI 10.1002/hep.26717
narrative_reviewCited 603×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Nonalcoholic fatty liver disease (NAFLD), particularly the NASH subtype and advanced fibrosis, is an independent risk factor for increased incidence and mortality of cardiovascular disease (CVD).Good
- Ultrasound-defined NAFLD is associated with a two- to five-fold increased risk of developing Type 2 Diabetes (T2DM), independent of lifestyle and metabolic confounders.Good
- Nonalcoholic steatohepatitis (NASH) is associated with a significantly higher risk of colorectal adenomas and cancer compared to simple steatosis or healthy controls.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →